Solid Biosciences Inc (SLDB)

$8.25

-0.01

(-0.12%)

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Solid Biosciences Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 41.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 319.9%

Performance

  • $7.98
    $8.57
    $8.25
    downward going graph

    3.27%

    Downside

    Day's Volatility :6.88%

    Upside

    3.73%

    downward going graph
  • $1.81
    $15.05
    $8.25
    downward going graph

    78.06%

    Downside

    52 Weeks Volatility :87.97%

    Upside

    45.18%

    downward going graph

Returns

PeriodSolid Biosciences IncRussel 2000Index (Russel 2000)
3 Months
-14.86%
0.0%
0.0%
6 Months
139.83%
0.0%
0.0%
1 Year
32.0%
0.0%
0.0%
3 Years
-84.81%
-22.6%
-22.6%

Highlights

Market Capitalization
317.0M
Book Value
$6.2
Earnings Per Share (EPS)
-3.93
Wall Street Target Price
16.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-30.67%
Return On Equity TTM
-56.79%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
13.6M
EBITDA
-101.7M
Diluted Eps TTM
-3.93
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.71
EPS Estimate Next Year
-2.69
EPS Estimate Current Quarter
-0.64
EPS Estimate Next Quarter
-0.64

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Solid Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
8
Hold
3
3
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 100.0%

Current $8.25
Target $16.50

Technicals Summary

Sell

Neutral

Buy

Solid Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Solid Biosciences Inc
Solid Biosciences Inc
-17.5%
139.83%
32.0%
-84.81%
-89.95%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Solid Biosciences Inc
Solid Biosciences Inc
0.15
NA
NA
-2.71
-0.57
-0.31
NA
6.2
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Solid Biosciences Inc
Solid Biosciences Inc
Buy
$317.0M
-89.95%
0.15
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Institutional Holdings

  • Perceptive Advisors LLC

    18.00%
  • RA Capital Management, LLC

    11.28%
  • Bain Capital Life Sciences Investors, LLC

    10.51%
  • Adage Capital Partners Gp LLC

    6.62%
  • HHG PLC

    4.71%
  • SILVERARC CAPITAL MANAGEMENT, LLC

    3.45%

Company Information

solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.

Organization
Solid Biosciences Inc
Employees
88
CEO
Mr. Ian F. Smith A.C.A., C.P.A.
Industry
Health Technology

FAQs